Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date Sort descending | Expire Date | Purpose |
|---|---|---|---|---|---|
| Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | RFA-CA-24-018 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to… More | ||
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) | RFA-CA-24-017 | NCI | The goal of this FOA is to advance cancer model systems that recapitulate human immunity in the tumor microenvironment to improve the predictivity of immuno-oncology studies. Proposed research… More | ||
| Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | RFA-CA-24-019 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high-value informatics research… More | ||
| Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) | RFA-CA-24-016 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the… More | ||
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | PAR-24-085 | NCI | The purpose of this reissuance is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and… More | ||
| Single Source: The NIGMS Human Genetic Cell Repository (U42 - Clinical Trial Not Allowed) | PAR-24-055 | NIGMS | The purpose of this NOFO is to support the NIGMS Human Genetic Cell Repository (HGCR). The repository will maintain the current collection of cell cultures and DNA samples and will acquire,… More | ||
| Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | PAR-24-072 | NCI | Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the… More | ||
| Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools to Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional) | RFA-DA-25-028 | NIDA | The purpose of this funding opportunity is to support the development of Clinical Outcome Assessments (COA) for Substance Use Disorders (SUD). The COA development plan is expected to progress into… More | ||
| Research Initiative for Vaccine and Antibiotic Allergy (UG3/UH3 Clinical Trial Not Allowed) | RFA-AI-24-002 | NIAID | The purpose of this notice of funding opportunity (NOFO) is to support research that enhances understanding of the mechanisms and management of vaccine and antibiotic drug allergy. | ||
| Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required) | PAR-24-090 | NCCIH | This notice of funding opportuntity (NOFO) encourages applications for investigator-initiated multi site clinical trials (e.g., efficacy, effectiveness, or pragmatic trials) to study the effects of… More |